Clinical trial
A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)
NCT01999777 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2013
- Completion date
- August 31, 2015
- Enrollment
- 62 (actual)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.